Volume-targeted Versus Pressure-limited Noninvasive Ventilation in Patients With Acute Hypercapnic Respiratory Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02538263 |
Recruitment Status :
Completed
First Posted : September 2, 2015
Last Update Posted : May 22, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Hypercapnic Respiratory Failure | Device: Volume-targeted noninvasive ventilation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 58 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | January 2013 |
Actual Primary Completion Date : | December 2013 |
Actual Study Completion Date : | December 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Volume-targeted noninvasive ventilation
For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
|
Device: Volume-targeted noninvasive ventilation |
No Intervention: Pressure-limited noninvasive ventilation
For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
|
- The decrease of arterial partial pressure of carbon dioxide (PaCO2) values from baseline to 6 hours after randomization [ Time Frame: 6 hours after randomization ]PaCO2 value at baseline minus PaCO2 value at 6 hours after randomization

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- acute hypercapnic respiratory failure (AHRF)
- arterial pH <7.35 and ≥7.25
- PaCO2 >45 mmHg
Exclusion Criteria:
- age <18 years
- excessive amount of respiratory secretions or weak cough
- upper airway obstruction
- recent oral, facial or cranial trauma or surgery
- recent gastric or esophageal surgery
- severe metabolic acidosis; severe abdominal distension
- cardiac or respiratory arrest
- PaO2/FiO2 <150 mmHg
- pneumothorax
- severe ventricular arrhythmia or myocardial ischemia
- severe hemodynamic instability despite fluid repletion and use of vasoactive agents
- active upper gastrointestinal bleeding
- lack of cooperation
- refusal to receive NIV

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02538263
China | |
Beijing Institute of Respiratory Medicine, Department of respiratory and critical care medicine, Beijing Chao-Yang Hospital Jingxi Campus, Capital Medical University | |
Beijing, China |
Responsible Party: | Zujin Luo, Attending physician, Beijing Chao Yang Hospital |
ClinicalTrials.gov Identifier: | NCT02538263 |
Other Study ID Numbers: |
BeijingCYH-ICU-001 |
First Posted: | September 2, 2015 Key Record Dates |
Last Update Posted: | May 22, 2019 |
Last Verified: | May 2019 |
Respiratory Insufficiency Hypercapnia Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |